743
Views
1
CrossRef citations to date
0
Altmetric
EDITORIAL NOTE

Hexokinase: A Glycolytic Enzyme with an Inflammatory Ischemia and Reperfusion Connection

&

Hydroxyl radicals are known to promote inflammation (Citation1, 2). One way that hydroxyl radicals can increase is due to ischemia-reperfusion (I/R) injury. Ultimately I/R injury affects the mitochondrial membrane and the apoptotic processes that normally occur. The mitochondria play a key role in the fate of the cell, determining whether or not the cell undergoes apoptosis. When there is an increase in hydroxyl radicals the lipids in the mitochondrial membrane begin to react with the hydroxyl radicals resulting in the mitochondrial membrane becoming leaky. A leaky mitochondrial membrane allows calcium that is normally kept at low concentrations in the mitochondria to be dramatically increased, wreaking havoc on the cell calcium homeostasis. The precise signaling pathways involved in calcium regulation that ultimately affect cell death are not well understood (Citation3). Cell death is a serious consequence, thus there are many factors that affect cell death, including Akt, Bax, and Bcl2. Akt inhibits cell death and has a significant role in cell survival and tumor formation (Citation4, 5). A glycolytic enzyme, hexokinase that has been overlooked in the past has recently been given some attention due to its interaction with Akt. How Akt, hexokinase and hydroxyl radicals interact to affect cell survival or cell death is currently unknown and is the reason for this editorial. As new advances are incorporated into the basic sciences of glycolysis and Akt and the clinical sciences of ischemia and reperfusion injury, translational efforts will be more frequently considered and applied. It is our ultimate goal to encourage investigators to utilize concepts presented here to move forward in the field of ischemia and reperfusion.

I/R injury results in an increase in inflammation through many cytokines, including TNF-α. Inflammation has been shown to increase a person's cancer risk (Citation6). The relationship between TNF-α and Akt continues to be defined, however Yang et al. have shown a relationship between Akt and TNF-α in hepatocellular carcinogenesis (Citation7). Additionally, a relationship has been established between hexokinase and Akt (Citation8). There are four hexokinase isoforms; hexokinase I and II are both considered mitochondrial hexokinases because they can bind to the mitochondrial membrane (Citation9). The relationship between hexokinase and Akt is currently being investigated to better understand which isoform of hexokinase is involved in cell survival. Due to the mitochondrial role as a gatekeeper of apoptosis, the ability of hexokinase II to bind to the mitochondrial membrane has serious implications on apoptosis and cell survival (Citation10).

Akt has been established as a pro-survival signaling protein (Citation11) that regulates signaling upstream of hexokinase (Citation12). With the discovery of hexokinase II as a pro-survival enzyme new research is currently underway to explore the role of hexokinase II in cancer (Citation13-15). Thus, hexokinase is an enzyme with other important functions beyond being the first enzyme in the glycolytic pathway. As such, hexokinases are beginning to be categorized as inflammatory regulatory proteins (Citation16). Defining the interaction of hexokinase with inflammatory proteins such as TNF-alpha will ultimately help our understanding of the process of host cell death. We believe, that the establishment of these relationships will help to further define the mechanisms behind I/R injury, cancer and other inflammatory disease processes.

REFERENCES

  • Pisoschi AM, Pop, A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem 2015; 97:55-74.
  • Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH. Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant. 2004; 9:81-3.
  • Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg. 2005; 18:335-50.
  • Toledo-Pereyra LH, Lopez-Neblina F, Reuben JS, Toledo AH, Ward PA. Selectin inhibition modulates Akt/MAPK signaling and chemokine expression after liver ischemia-reperfusion. J Invest Surg. 2004; 17:303-313.
  • Chen H, Liang ZW, Wang ZH, Zhang, JP, Hu B, Xing XB, Cai WB. Akt activation and inhibition of Cytochrome C release: mechanistic insights into Leptin-promoted survival of type II alveolar epithelial cells. J Cell Biochem 2015; 116:2313-24.
  • Izano M, Wei EK, Tai C, Swede H, Gregorich S, Harris TB, Klepin H, Satterfield S, Murphy R, Newman AB, Rubin SM, Braithwaite D. Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study. Int J Cancer 2015.
  • Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H, Jiang J, Chen J, Chen G, Wu B. b-Arrestin 1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nat Commun 2015; 6:1-14.
  • Garber K. Energy deregulation: licensing tumors to grow. Science 2006; 312:1158-1159.
  • Schindler A, Foley E. Hexokinase 1 blocks apoptotic signals at the mitochondria. Cellular Signalling 2013; 25:2685-2692.
  • Lemeshko VV. VDAC electrons: 1. VDAC-hexo(gluco)kinase generator of the mitochondrial outer membrane potential. Biochim Biophys Acta 2014; 1838:1362-71.
  • Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 15:4217-26.
  • Majewski N, Nogueira V, Robey RB, Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cel Biol 2004; 24:730-40.
  • Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB, Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 12:213-28.
  • Patra KC, Hay N. Hexokinase 2 as oncotarget. Oncotarget 2013; 4:1862-3.
  • Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N: Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015; 60:420-6.
  • Calmettes G, Ribalet B, John S, Korge P, Ping P, Weiss JN. Hexokinases and cardioprotection. J Mol Cell Cardiol 2015: 78:107-15.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.